Please use this identifier to cite or link to this item: https://hdl.handle.net/1/2054
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBack, Michael-
dc.contributor.authorEade, Thomas-
dc.contributor.authorKneebone, Andrew-
dc.contributor.otherOh, B.-
dc.contributor.otherLamoury, G.-
dc.contributor.otherCarroll, S.-
dc.contributor.otherMorgia, M.-
dc.contributor.otherHruby, G.-
dc.contributor.otherStevens, M.-
dc.contributor.otherBoyle, F.-
dc.contributor.otherClarke, S.-
dc.contributor.otherCorless, B.-
dc.contributor.otherMolloy, M.-
dc.contributor.otherRosenthal, D.-
dc.date.accessioned2021-11-26T02:54:09Z-
dc.date.available2021-11-26T02:54:09Z-
dc.date.issued2021-05-
dc.identifier.citation13(10):2353en
dc.identifier.issn2072-6694en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/2054-
dc.description.abstractBACKGROUND: Gastrointestinal (GI) toxicities are common adverse effects of pelvic radiotherapy (RT). Several recent studies revealed that toxicity of RT is associated with dysbiosis of the gut microbiome. METHOD: A literature search was conducted in electronic databases Medline, PubMed, and ScienceDirect, with search terms "microbiome and/or microbiota" and "radiotherapy (RT) and/or chemoradiation therapy (CRT)" and "cancer", and the relevant literature were selected for use in this article. RESULTS: Eight prospective cohort studies were selected for review with a total of 311 participants with a range of 15-134 participants within these studies. The selected studies were conducted in patients with gynaecological (n = 3), rectal (n = 2), or prostate cancers (n = 1), or patients with various types of malignancies (n = 2). Three studies reported that cancer patients had significantly lower alpha diversity compared with healthy controls. Seven studies found that lower alpha diversity and modulated gut microbiome were associated with GI toxicities during and after pelvic RT (n = 5) and CRT (n = 2), whereas one study found that beta diversity was related to a complete response following CRT. Two further studies reported that fatigue was associated with dysbiosis of the gut microbiome and low alpha diversity during and after RT, and with dysbiosis of the gut microbiome and diarrhoea, respectively. CONCLUSION: Gut microbiome profiles are associated with GI toxicities and have the potential to predict RT/CRT-induced toxicities and quality of life (QoL) in patients undergoing those treatments. Further robust randomized controlled trials (RCTs) are required to elucidate the effect of gut microbiome profiles on RT-related adverse effects and responses to RT.en
dc.description.sponsorshipRadiation Oncologyen
dc.description.sponsorshipCentral Coast Cancer Centreen
dc.subjectCanceren
dc.subjectRadiotherapyen
dc.titleThe Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Reviewen
dc.typeJournal Articleen
dc.identifier.doihttp://orcid.org/0000-0003-2363-8333en
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34068216/en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesGosford Hospitalen
dc.identifier.journaltitleCancersen
dc.type.studyortrialReviews/Systematic Reviewsen
dc.relation.orcidhttp://orcid.org/0000-0003-2363-8333en
dc.originaltypeTexten
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Oncology / Cancer
Radiology
Show simple item record

Page view(s)

30
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.